AMY MCCORMICK: Open Payments
NPI 1275874273 · BETTENDORF, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,562 in 105 payments from 15 companies in 2025. Trend: 2023 $474 · 2024 $635 · 2025 $1,562
Food & beverage: $1,562
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $305 |
| Otsuka America Pharmaceutical, Inc. | 18 | $241 |
| TG Therapeutics, Inc. | 2 | $238 |
| Neurocrine BioSciences, Inc. | 30 | $178 |
| Teva Pharmaceuticals USA, Inc. | 10 | $147 |
| Axsome Therapeutics, Inc. | 4 | $97 |
| E.R. Squibb & Sons, L.L.C. | 5 | $96 |
| Lundbeck LLC | 3 | $45 |
| Vanda Pharmaceuticals Inc. | 2 | $44 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $41 |
Products named: VRAYLAR, BRIUMVI, INGREZZA, REXULTI, ABILIFY ASIMTUFII, Auvelity, COBENFY, AUSTEDO XR.
Industry payments across IA — which companies pay providers there.
